Re: GYN: Menostar

From: Zachariah Newton (zbnewton@bellsouth.net)
Tue Sep 28 23:12:35 2004


The matter of long interval progestational additive to sustained low dosage estrogen maintenance has theoretical merit and potential clinical benefit.

The limiting issue is the outlier who develops an endometrial malignancy while under such a regimen that has not been standardized The liability issue will devastate the prescriber, regardless of benefit/risk arguments.

If the uterus is there with estrogen therapy, progesterone/progestin additive on a standardized basis is obligatory. By today's standards, p-therapy every 4 or 6 months for the individual who does develop endometrial carcinoma will come back to bite you.

Zach Newton Z. B. Newton, III, M.D. Atlanta/ Gyn





use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
Returns per screen: Require all keywords:

Return to  OB-GYN-L Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Fri May 2 04:38:52 2008

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.